TFFP - TFF Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

TFF Pharmaceuticals, Inc.

1751 River Run
Suite 400
Fort Worth, TX 76107
United States
(817) 438-6168

Full-time employees15

Key executives

NameTitlePayExercisedYear born
Dr. Harlan F. WeismanCEO, Interim Pres & Vice Chairman594.48kN/A1952
Mr. Kirk Allen ColemanCFO, Treasurer & Sec.382.22kN/A1974
Mr. Christopher CanoCOO & VP of Bus. Devel.353.62kN/A1972
Mr. Paul F. ManleyHead of Regulatory AffairsN/AN/AN/A
Dr. Zamaneh Mikhak M.D.Chief Medical OfficerN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Corporate governance

TFF Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.